This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Dec. 5, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it will be hosting an investor event for research analysts and institutional investors on Thursday, December 12, 2013 at 8:30 p.m. EST in San Antonio, Texas. Mark Capone, president of Myriad Genetic Laboratories; Richard Wenstrup M.D., chief medical officer; John Ryan, senior director of operations; and Larry Geier M.D., assistant professor at Kansas University Medical School will be presenting at the event. The focus of the meeting will be on Myriad's new myRisk Hereditary Cancer™ test. If you are interested in attending please contact Myriad's investor relations team for the event details.
A live webcast of Myriad's Analyst and Investor Day can be accessed by visiting the investor relations section of the Company's website at
http://investor.myriad.com/index.cfm. A replay of this presentation will be archived on the Myriad website for 24 hours following the completion of the investor event.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:
CONTACT: Media Contact: